AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MESO
  4. [6-K] Mesoblast Limited American Current Report (Foreign Issuer)

[6-K] Mesoblast Limited American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Filing content is currently unavailable.

Source:

Stock MESO logo
Mesoblast

NASDAQ:MESO

MESO Rankings

#2048 Ranked by Market Cap
N/A Ranked by Dividends

MESO Latest News

Aug 28, 2025
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil庐
Aug 27, 2025
Mesoblast Financial Results and Corporate Update Webcast
Jul 17, 2025
Successful Commercial Launch of Ryoncil庐
Jun 30, 2025
Mesoblast and FDA Align on Key Items for Revascor庐 Biologic License Application in Ischemic Heart Failure
Jun 11, 2025
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor庐 in Ischemic Heart Failure and Label Extension for Ryoncil庐 in Adults With GvHD

MESO Latest SEC Filings

Aug 29, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Aug 29, 2025
[20-F] Mesoblast Limited American Files Annual Report (Foreign Issuer)
Aug 27, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Jul 14, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Jul 1, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)

MESO Stock Data

2.05B
127.76M
0.06%
2.69%
1.86%
Biotechnology
Healthcare
Australia
Melbourne